Literature DB >> 6627007

Characterization and regional distribution of serotonin S2-receptors in human brain.

A Schotte, J M Maloteaux, P M Laduron.   

Abstract

[3H]Ketanserin binding was characterized in vitro in human brain homogenates and the regional distribution of the sites was determined. In human brain, [3H]ketanserin was found to bind on serotonin (5-HT) S2-receptors; only 5-HT antagonists competed with the labelled ligand at nanomolar concentrations; other drugs were much less active or inactive. Special attention was paid to the choice of a displacer, here methysergide, to determine the blank value (non-displaceable binding). [3H]Ketanserin binding in human brain displayed similar binding characteristics to the S2-receptor in the rat frontal cortex, high affinity (Kd 0.69 nM) and relatively slow dissociation rate. The regional distribution of serotonin S2-receptors labelled with [3H]ketanserin was studied in 30 different regions of human brain. The highest number of receptors was measured in the cortex. However, within the cortex the distribution was also inhomogeneous, a much lower number of sites being found in the pre- and post-central gyri. In the dopaminergic areas and the cerebellum the number of sites was quite low, and only few binding sites were detected in the corpus callosum, the medulla and the hypophysis. The large number of serotonin S2-receptors in the human cortex suggests that serotonin has an important role in this brain region.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6627007     DOI: 10.1016/0006-8993(83)90729-1

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  11 in total

1.  MDMA ("Ecstasy") and its association with cerebrovascular accidents: preliminary findings.

Authors:  L Reneman; J B Habraken; C B Majoie; J Booij; G J den Heeten
Journal:  AJNR Am J Neuroradiol       Date:  2000 Jun-Jul       Impact factor: 3.825

2.  [3H]ketanserin binding in human brain postmortem.

Authors:  D Marazziti; A Rossi; L Palego; G Giannaccini; A Naccarato; A Lucacchini; G B Cassano
Journal:  Neurochem Res       Date:  1997-06       Impact factor: 3.996

3.  PET measurement of D2 and S2 receptor binding of 3-N-[( 2'-18F]fluoroethyl)spiperone in baboon brain.

Authors:  H H Coenen; K Wienhard; G Stöcklin; P Laufer; I Hebold; G Pawlik; W D Heiss
Journal:  Eur J Nucl Med       Date:  1988

4.  Pharmacological and behavioral characterization of the 5-HT2A receptor in C57BL/6N mice.

Authors:  John P Dougherty; Vincent J Aloyo
Journal:  Psychopharmacology (Berl)       Date:  2011-02-22       Impact factor: 4.530

5.  3H-spiperone binding sites in post-mortem brains from schizophrenic patients: relationship to neuroleptic drug treatment, abnormal movements, and positive symptoms.

Authors:  J Kornhuber; P Riederer; G P Reynolds; H Beckmann; K Jellinger; E Gabriel
Journal:  J Neural Transm       Date:  1989       Impact factor: 3.575

6.  Autoradiographic localization of binding sites for 3H-serotonin and 3H-ketanserin on neurones and astrocytes of cultured rat brain stem and spinal cord.

Authors:  E Hösli; L Hösli
Journal:  Exp Brain Res       Date:  1987       Impact factor: 1.972

7.  [3H]MDL 100,907: a novel selective 5-HT2A receptor ligand.

Authors:  M P Johnson; B W Siegel; A A Carr
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-07       Impact factor: 3.000

8.  Multicompartmental study of fluorine-18 altanserin binding to brain 5HT2 receptors in humans using positron emission tomography.

Authors:  F Biver; S Goldman; A Luxen; M Monclus; M Forestini; J Mendlewicz; F Lotstra
Journal:  Eur J Nucl Med       Date:  1994-09

Review 9.  The dopamine hypothesis of schizophrenia: limbic interactions with serotonin and norepinephrine.

Authors:  J N Joyce
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

10.  5-HT2 and D2 dopamine receptor occupancy in the living human brain. A PET study with risperidone.

Authors:  S Nyberg; L Farde; L Eriksson; C Halldin; B Eriksson
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.